https://pharmatlas.org/ 2026-04-06T14:36:24+00:00 https://pharmatlas.org/ https://pharmatlas.org/lib/exe/fetch.php?media=logo.png text/html 2026-02-12T19:45:16+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=respiratory:drugs:leukotriene_modifiers&rev=1770925516&do=diff Leukotriene Modifiers Leukotriene modifiers target the leukotriene arm of the arachidonic acid inflammatory pathway. They are primarily used in: * Asthma * Allergic Rhinitis * Aspirin-exacerbated respiratory disease (AERD) They reduce bronchoconstriction, mucus production, and airway inflammation. text/html 2026-02-12T19:47:02+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=respiratory:drugs:montelukast&rev=1770925622&do=diff Montelukast Classification * Leukotriene Receptor Antagonist (CysLT1 blocker) Parent class: * Leukotriene Modifiers ---------- Mechanism of Action Montelukast selectively blocks the CysLT1 receptor. Leukotrienes (LTC4, LTD4, LTE4) normally cause: * Bronchoconstriction text/html 2026-02-12T19:49:45+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=respiratory:drugs:zafirlukast&rev=1770925785&do=diff Zafirlukast Classification * Leukotriene Receptor Antagonist (CysLT1 blocker) Parent class: * Leukotriene Modifiers ---------- Mechanism of Action Zafirlukast selectively blocks the CysLT1 receptor. Leukotrienes (LTC4, LTD4, LTE4) normally cause: * Bronchoconstriction text/html 2026-02-12T19:50:26+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=respiratory:drugs:zileuton&rev=1770925826&do=diff Zileuton Classification * 5-Lipoxygenase (5-LO) Inhibitor * Leukotriene synthesis inhibitor Parent class: * Leukotriene Modifiers ---------- Mechanism of Action Zileuton inhibits the 5-lipoxygenase enzyme. Normal pathway: Arachidonic acid ↓ (5-lipoxygenase) Leukotrienes (LTA4 → LTC4, LTD4, LTE4)